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Effects of angiotensin-converting enzyme inhibitors on the about the concurrent use of angiotensin-converting en-
treatment of anemia with erythropoietin. zyme (ACE) inhibitors on the effectiveness of rHuEPO
Background. The hypothesis that angiotensin-converting treatment for anemia.enzyme (ACE) inhibitors interfere with the treatment of ane-
Angiotensin-converting enzyme inhibitors are oftenmia with recombinant human erythropoietin (rHuEPO) remains
the drugs of choice to treat the hypertension found incontroversial. To test this hypothesis, a retrospective analysis
was conducted in a large group of hemodialysis patients with patients with renal anemia. A number of studies have
renal anemia. reported that ACE inhibitors antagonized the effects of
Methods. The effects of ACE inhibitors in these patients rHuEPO on the treatment of anemia in hemodialysiswere evaluated by measuring the weekly increment in hemato-
patients [1–5]. While a number of possible mechanismscrit (Hct) values within 12 weeks of the initiation of rHuEPO
have been identified, there is no consensus. Since angio-treatment. Results from 2213 rHuEPO naı¨ve patients were com-
pared between patients receiving rHuEPO alone and patients tensin II is reported to facilitate erythropoiesis [6, 7] and
receiving both rHuEPO and ACE inhibitors. Because of the endogenous erythropoietin production [8], ACE inhibi-
demographic differences between the two groups, a propensity
tors may exacerbate anemia by reducing angiotensin IIscore was used to eliminate the influence of confounding factors
levels. ACE inhibitors also increase plasma Ac-SDKPand to match the patient population in these two patient groups.
Multiple regression analysis also was performed. (N-acetyl-seryl-aspartyl-lysyl-proline) [9, 10] by prevent-
Results. When the Hct values were compared directly be- ing the degradation of Ac-SDKP by ACE [11]. Increased
tween the two groups or were assessed by multiple regression plasma Ac-SDKP prevents the cycling of hematopoietic
analysis, no effect of ACE inhibitors was observed (P  0.941
stem and progenitor cells [12, 13]. These mechanisms,and P  0.308, respectively). When the effects of ACE inhibi-
however, may be bypassed or overcome by exogenoustors on the treatment of anemia with rHuEPO were analyzed
in 329 patients extracted from each group by their propensity rHuEPO administration.
score, Hct did not differ between the two groups (P 0.355). While some clinical studies report worsening effects
Conclusions. These results suggest that ACE inhibitors have of ACE inhibitors on anemia treated with erythropoietinno effect on the rHuEPO treatment for anemia in hemodialysis
[1–5], other studies of hemodialysis patients have foundpatients who were treated with a relatively low dose of ACE
no effect of ACE inhibitors [14–17]. Consequently, thereinhibitors and low-dose rHuEPO.
are no definitive conclusions reached on the role of ACE
inhibitors during the treatment of anemia. Generally,
the question has been examined with a limited sampleSince renal anemia directly influences the quality of
size and treatment condition both retrospectively andlife (QOL), prognosis, and rehabilitation of patients into
prospectively. A large clinical study is necessary to re-society, an effective treatment is critically important. Re-
solve the effects of ACE inhibitors on rHuEPO-depen-combinant human erythropoietin (rHuEPO) has been
introduced into the clinic and is currently used through- dent treatment of renal anemia. Our study presents data
out the world to treat patients with anemia. While many from a large post-marketing survey that retrospectively
investigations have confirmed the efficacy and safety of identified 2213 patients who met our selection criteria.
rHuEPO treatment for renal anemia, there is concern We compared two groups of patients with renal anemia
that was being treated with rHuEPO both with and with-
out concurrent ACE inhibitor therapy. The analyses in-Key words: hemodialysis, hematocrit, hypertension, blood pressure,
erythropoiesis, quality of life, kidney, renal anemia. cluded direct comparison and multiple regression analy-
sis to determine the degree of influence of demographicsReceived for publication December 12, 2000
on the individual’s level of anemia. Finally, patients wereand in revised form June 29, 2001
Accepted for publication June 29, 2001 matched and compared after reducing the influence of
demographics through the use of propensity scores. 2001 by the International Society of Nephrology
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Table 2. Comparison of the weekly increment in hematocritTable 1. Angiotensin-converting enzyme (ACE) inhibitors used in
combination with recombinant human erythropoietin (rHuEPO) (Hct, %/week) values between groups
Difference in HctRange
of dose N of Proportion N of P value
cases Hct 95% CIName of drug mg/day cases of total %
Enalapril maleate 2.5–15 113 34.3 Monotherapy 1884 0.5610.396 0.002
P0.941Captopril 12.5–150 96 29.2
Alacepril 25–100 41 12.5 Combination therapy 329 0.5620.361 0.041 to 0.045
Cilazapril 0.5–2 28 8.5
Delapril hydrochloride 25–100 27 8.2
Lisinopril 2.5–20 19 5.8
Imidapril hydrochloride 2.5 3 0.9
Benazapril hydrochloride 5–10 2 0.6 were analyzed with the Student t test for the significance
of differences between the two groups. Tests were con-
ducted with a two-sided P value, and the significance
level was 0.05.
METHODS
Patient population
RESULTS
A post-marketing survey was conducted on 3585 hemo-
Patient demographicsdialysis patients treated for renal anemia with rHuEPO
(ESPO injection; Kirin-Sankyo, Tokyo, Japan) at 466 From the original group of 2213 patients entered into
this study, 1884 (85.1%) patients were assigned to themedical institutions in Japan from January 1990 to De-
cember 1994. Data were collected retrospectively for anal- rHuEPO treatment group (subsequently referred to as
the monotherapy group), and 329 (14.9%) patients wereysis from a 12-week period after initiation of the rHuEPO
treatment. assigned to the rHuEPO  ACE inhibitors treatment
group (combination therapy group). The ACE inhibitorsCriteria for patient exclusion from the survey included:
(1) the patient withdrew from ACE inhibitor therapy used by patients in this study were enalapril maleate in
113 patients (34.3%), captopril in 96 patients (29.2%),during the 12-week period; (2) the patient was not ini-
tially treated with rHuEPO; (3) the patient received and other preparations in 120 patients (36.5%; Table 1).
blood transfusion during the 12-week period; or (4) any
Effect of ACE inhibitors on Hctof nine variables (sex, age, body weight, history of dial-
ysis, pretreatment hematocrit, rHuEPO dose, concomi- Simple comparison between groups. When Hct mea-
surements were compared between the two groups, theretant administration of an iron preparation, pretreatment
serum iron concentration, or classification of underlying was an increase of 0.561% per week in the monotherapy
group and 0.562% per week in the combination therapydiseases) was not available. From the original 3585 pa-
tients, 2213 were identified who could be included in this group (Table 2), but this was not statistically different
(P  0.941, 95% CI, 0.041 to 0.045% per week). A di-analysis.
rect comparison of the two groups may be biased by dif-
Statistical methods ferences in the patient populations between the groups.
The result may have underestimated the effects of ACEThe patients were allocated into two groups for analy-
sis. One group received rHuEPO and ACE inhibitors inhibitors on rHuEPO-dependent recovery from ane-
mia. When the distribution of demographic data of pa-in combination and the other group received rHuEPO
alone. Weekly incremental hematocrit (Hct) values tients were compared between the two groups, statisti-
cally significant differences in sex (P  0.001), age (P were calculated from the medical records of each patient
and were compared between the two groups. The effects 0.001), body weight (P  0.001), history of dialysis (P 
0.045), iron preparation (P  0.018), and underlyingof ACE inhibitors on the rHuEPO treatment of renal
anemia were measured three ways: (1) The Hct values disease (P  0.003) were found (Table 3). There was no
significant difference in the dose of rHuEPO (97.8 were compared between the two groups; (2) Hct values
were compared between the two groups after multiple 44.6 U/kg/week vs. 97.7  41.6 U/kg/week; dose was
considered the most important influence on anemia), norregression analysis using Hct as a response variable
and using ACE inhibitors and patient demographics as in the pretreatment Hct values or serum iron concentra-
tions between the two groups.predictor variables; and (3) Hct values were compared
between the two groups of patients after matching for Multiple regression analysis. Since there were demo-
graphic differences in the two groups, we examined thepropensity score to eliminate the influence of confound-
ing demographic factors [18]. influence of these differences on the recovery from ane-
mia. The effects of ACE inhibitors on Hct were ana-All data were expressed as mean SD. Nominal data
were analyzed with the chi-square test, and metric data lyzed by a multiple regression analysis using Hct as a
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Table 3. Comparison of demographic data between groups
Groups
Combination Intergroup
Monotherapy therapy comparison
Variable N  1884 N  329 P value
Sex
Male 1025 (54.4) 215 (65.3) 0.001a
Female 859 (45.6) 114 (34.7)
Age years 56.913.3 53.613.4 0.001a
Body weight kg 53.19.5 55.010.1 0.001a
History of dialysis
1 year 1006 (53.4) 156 (47.4) 0.045a
1 year 878 (46.6) 173 (52.6)
Pre-treatment Hct % 22.03.0 21.73.1 0.086
rHuEPO dose U/kg/week 97.844.6 97.741.6 0.971
Iron preparation
Not used 1065 (56.5) 209 (63.5) 0.018a
Used 819 (43.5) 120 (36.5)
Serum iron concentration lg/dL 69.037.2 67.834.6 0.550
Underlying disease
Chronic glomerulonephritis 1153 (61.2) 175 (53.2) 0.003a
Diabetic nephrosis 422 (22.4) 102 (31.0)
Other 309 (16.4) 52 (15.8)
Propensity score 0.1440.061 0.1750.066 0.001a
a Statistically significant
Table 4. Multiple regression analysis
Parameter Standard T for H0:
Variable estimated error Parameter  0 Prob  |T|
Intercept 1.41375 0.10132 13.954 0.001
ACE inhibitorsa 0.02084 0.02044 1.020 0.308
Sexb 0.05522 0.01704 3.241 0.001
Age years 0.00108 0.00057 1.915 0.056
Body weight kg 0.00197 0.00096 2.051 0.040
History of dialysisc 0.07273 0.01489 4.883 0.001
Pre-treatment Hct 0.05012 0.00243 20.590 0.001
rHuEPO dose U/kg/week 0.00184 0.00018 10.158 0.001
Iron preparationa 0.07360 0.01482 4.968 0.001
Serum iron concentration lg/dL 0.00067 0.00020 3.353 0.001
Chronic glomerulonephritisd 0.00595 0.02007 0.297 0.767
Diabetic nephropathyd 0.03985 0.02358 1.690 0.091
R2  0.2607.
a Scored as 0  not used and 1  used
b Scored as 0  male and 1  female
c Scored as 0  1 year and 1  1 year
d Scored as 0  absent and 1  present
response variable and using the presence or absence of Comparison between matched groups. Since we did
not control the treatment assignment in this survey, theACE inhibitors and demographic data of patients as
predictor variables (Table 4). ACE inhibitors reduced groups may have differences in their observed covariates,
which could lead to biased estimates of the treatmentthe rHuEPO-dependent Hct increase by 0.021% per
week, but this was not statistically significant (P 0.308). effects. The propensity score was defined as a conditional
probability for the ACE inhibitor treatment to be af-However, this regression model seemed inappropriate
for statistical evaluation of data in this analysis, because fected by the given covariates. When the propensity score
differed between groups, an accurate conclusion mayboth the regression coefficient for the whole multiple
regression models was low (R2  0.2607) and there were not be drawn because of interference by the additional
confounding factors. To eliminate the influence of con-correlations between some of the predictor variables
(data not shown). To account for these problems better founding factors, methods such as matching patients be-
tween groups by propensity score or stratification of pa-and to conduct a model-independent analysis, the two
groups were matched using a propensity score. tients by propensity scores have been used in prior studies
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Table 5. Demographic data of patients matched for propensity score
Groups
Combination Intergroup
Monotherapy therapy comparison
Variable N  329 N  329 P value
Sex
Male 218 (66.3) 215 (65.3) 0.805
Female 111 (33.7) 114 (34.7)
Age years 54.112.9 53.613.4 0.629
Body weight kg 55.09.4 55.010.1 0.963
History of dialysis
1 year 157 (47.7) 156 (47.4) 0.938
1 year 172 (52.3) 173 (52.6)
Pre-treatment Hct % 21.53.2 21.73.1 0.468
rHuEPO dose U/kg/week 98.445.2 97.741.6 0.842
Iron preparation
Not used 202 (61.4) 209 (63.5) 0.573
Used 127 (38.6) 120 (36.5)
Serum iron concentration lg/dL 69.335.8 67.834.6 0.570
Underlying disease
Chronic glomerulonephritis 169 (51.4) 175 (53.2) 0.871
Diabetic nephrosis 108 (32.8) 102 (31.0)
Other 52 (15.8) 52 (15.8)
Propensity score 0.1750.066 0.1750.066 0.983
Table 7. Results of comparisonTable 6. Comparison of Hct after matching
Difference in Hct Effect of ACE inhibitors
Method on Hct %/week P valueN of Hct P value
cases % week 95% CI
Simple comparison 0.002 0.941
Regression analysis 0.021 0.308Monotherapy 329 0.5920.451 0.029
P0.355 Matching 0.029 0.355
Combination therapy 329 0.5620.361 0.092 to 0.033
[19, 20]. Our study employed the former method. By analysis comprised a comparison of the weekly Hct
matching patients in the two groups by propensity score, values within a 12-week study period in the monotherapy
the variables were balanced between the groups, and group (rHuEPO treatment alone) and combination ther-
interference of confounding factors related to the demo- apy group (rHuEPO with concurrent ACE inhibitor
graphic data removed from our analysis. The propensity treatment) using three methods (Table 7).
scores for the monotherapy group (0.144) and the combi- A simple comparison indicated no statistical signifi-
nation therapy group (0.175) were calculated using nine cance between the two groups (P  0.941). However,
variables. Using this method, there was a significant dif- some significant differences between the two groups were
ference in the score between the two groups (P 0.001). apparent when patient demographics were included that
As expected after matching, no significant bias in the may confound this analysis. Therefore, a multiple regres-
distribution of demographic data between the two groups sion analysis was conducted to eliminate the potentially
was found (Table 5). confounding factors related to patient demographics.
A comparison of Hct values between two groups Multiple regression analysis also showed no statistical
after matching the scores found that Hct was 0.592% importance for the ACE inhibitors (P  0.308). Finally,
per week for the monotherapy group and 0.562% per because of the biased distribution of patient demograph-
week for the combination therapy group (Table 6). The
ics in the two groups, patients were matched in the twodifference in Hct was not statistically significant (P 
groups by propensity score. This methodology elimi-0.355, 95% CI, 0.092 to 0.033% per week) between
nated confounding factors that potentially distort thethe two groups.
causal relationship between rHuEPO and ACE inhibitor
treatments. When the patients were matched for propen-
DISCUSSION sity score, the difference inHct between the two groups
was 0.029% per week, which was not statistically differ-The effects of ACE inhibitors on rHuEPO treatment
of renal anemia were evaluated in this analysis. The ent (P 0.355). Thus, we did not find a significant effect
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Fig. 1. Hypothetical relationships between an-
giotensin-converting enzyme (ACE) inhibitors
and the dose of recombinant human erythro-
poietin (rHuEPO) in the correction of anemia.
of ACE inhibitors on the rHuEPO treatment for renal received 150 mg/day; one patient received 100 mg/day,
and 94 patients received less than 75 mg/day. Most of theanemia, using the three methods of comparison.
Eight different ACE inhibitors were used in our analy- patients received a dose of 37.5 mg/day. Charytan et al
also used a low dose ACE inhibitor (enalapril maleate,sis. Apart from captopril and lisinopril, the other drugs
were prodrugs that are metabolized and converted into 11  10.7 mg/day) [14] compared with Albiter et al’s
study [3], and concluded that ACE inhibitors did nottheir active form mainly in liver. Regardless of their
metabolic pathway, no significant difference of the Hct affect the rHuEPO dose needed to treat anemia.
Similar to ACE inhibitor dosage, the typical rHuEPOwas observed among the patients treated with different
ACE inhibitors. For instance, Hct of captopril was dose used in Japan is lower than in other countries. In the
United States, the recommended range for a starting0.540% and that of enalapril malate was 0.594%. The
dose of ACE inhibitors used in this analysis was consid- dose of rHuEPO is 50 to 100 U/body weight three times
per week with a suggested targeted hematocrit value of 30ered relatively low compared to other studies [3–5, 16,
17]. For example, though a dose reduction in the initial to 36% [23]. In Japan, the recommendation for a starting
dose of rHuEPO is 3000 U/body three times per week.daily dosage is required, the daily maintenance dose of
enalapril maleate and captopril is 10 to 40 mg/day and The dose is reduced to 1500 U/body weight two to three
times per week or 3000 U/body two times per week50 to 450 mg/day, respectively, in Europe and the United
States [21, 22], while the recommended daily dose of when the hematocrit value reaches about 30%. These
recommendations for rHuEPO dosage were used in thisthese drugs in Japan is 5 to 10 mg/day and 37.5 to 75
mg/day, respectively. In our analysis, only three patients survey.
Taken together, our analysis shows that low-dose ACEtreated with enalapril maleate received 15 mg/day, and
110 patients received less than 10 mg/day. Most patients inhibitors do not have a negative effect on the correction
of anemia when low dose rHuEPO treatment is used.received a dose of 5 mg/day. Additionally, 96 patients
were treated with captopril at dosages ranging from 12.5 Our conclusions differ from earlier communications
reporting that ACE inhibitors reduced the effectivenessto 150 mg/day in our analysis. In this group, one patient
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Table 8. Comparison of values in six study cohorts
Reference No. of patients ACE inhibitors Epo dosage Outcome
Albiter et al [3] 19 on Enalapril Enalapril 10–20 mg/day On ACE-I 13810 U/kg/week 10.50.3 g/dL
18 on Nifedipine Captopril 40 mg/day Nifedipine 775 U/kg/week 10.40.2 g/dL
18 on Control Control 809 U/kg/week 10.30.2 g/dL
Erturk et al [4] 15 on ACE-I Enalapril 10–40 mg/day On ACE-I 208.399.0 U/kg/week 26.36.4%
→withdrawal Captopril 25–75 mg/day Off ACE-I 141.481.0 U/kg/week 29.46.5%
Perindopril 2 mg/day
Charytan et al [14] 32 on Enalapril Enalapril 1110.7 mg/day On ACE-I 173586871 U/week 32.14.4%
143 on Control Control 176127744 U/week 30.54.0%
Cruz et al [16] 24 on ACE-I Lisinopril 5–40 mg/day On ACE-I 52.8719.38 U/kg/treat 32.31.8%
24 on non-ACE-I Enalapril 2.5–40 mg/day Non ACE-I 50.6926.94 U/kg/treat 33.23.7%
Fosinopril 10–20 mg/day
Abu-Alfa et al [17] 33 Crossover (switched from) On ACE-I 50.024.1 U/kg/treat 32.71.9%
Lisinopril 24.28.8 mg/day
Captopril 28.015.7 mg/day Non ACE-I 48.026.6 U/kg/treat 33.12.1%
Enalapril 20.0 mg/day
(switched to)
Lisinopril 25.010.8 mg/day
Present study 329 on ACE-I Enalapril 2.5–15 mg/day On ACE-I 97.741.6 U/kg/week 0.5620.360%/week
329 on Control etc. Control 98.445.2 U/kg/week 0.5920.451%/week
of rHuEPO treatments in renal anemia. Albitar et al nisms may be observed only when a high-dose ACE
inhibitor is accompanied by a low dose rHuEPO. Theseshowed that the dose of rHuEPO required to maintain
a target hemoglobin concentration (10 g/dL) was findings taken together allow us to speculate that the
inhibitory effect of ACE inhibitors may be apparent onlygreater in the ACE inhibitor treatment group (138  10
U/kg/week) than in the control group (80  9 U/kg/ when high-dose ACE inhibitors and low-dose rHuEPO
(or a low target hematocrit value) are administered to-week). Most patients received a high dose of enalapril
gether to a hemodialysis patient (Fig. 1 and Table 8).(20 mg/day) in their study [3]. Erturk et al reported that
Results from 2213 hemodialysis patients were ob-after discontinuation of high-dose enalapril (10 to 40 mg/
tained, and we sought to eliminate confounding factorsday), the patients’ hematocrit increased from 26.3 
by matching patients by propensity score. We conclude6.4% to 29.8  6.3% while decreasing the dose of
that ACE inhibitors have no effect on the rHuEPO treat-rHuEPO from 208.3  99.0 U/kg/week to 141.4  81.0
ment in hemodialysis patients in our analysis. This lackU/kg/week [4]. In both of these studies, the targeted
of effect may be due to the relatively low dose of ACEhematocrit value was not high (about 30%), while the
inhibitors and rHuEPO used in Japan. Our analysis coulddose of ACE inhibitor used by patients was high. In
not identify the doses of ACE inhibitors and rHuEPOother words, these studies showed that high-dose ACE
that are critically important for the treatment of renalinhibitors exacerbated anemia when the rHuEPO dose
anemia. Further investigations with wider ranges of ACEwas low.
inhibitors and rHuEPO should be examined in a largeCruz et al conducted two studies, a retrospective analy-
cohort of patients to identify their interactions.sis and a prospective study based on their earlier retro-
spective study [16, 17]. Although an analytical weakness
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